Home › All Companies › ARWR › Quarterly Report

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — Quarterly Report

AI-Powered SEC Filing Analysis

← All ARWR filings
Latest Quarterly Report Filed: 2026-02-05

Key Insights

  • Arrowhead Pharmaceuticals reported a significant increase in revenue and net income for the quarter ended December 31, 2025, suggesting strong growth in its core business.
  • The company announced several new collaboration agreements with major pharmaceutical partners, indicating expanding opportunities in its drug pipeline.
  • Insider selling activity increased during the quarter, which may raise concerns about management's confidence in the company's near-term prospects.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ARROWHEAD PHARMACEUTICALS, INC.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.